SCHEMBL23042579

SCHEMBL23042579

COc1nc2ccc(B3OC(C)(C)C(C)(C)O3)cc2n1C(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SNCA P37840 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.39
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35
LPL P06858 9/20 0.35
LIPG Q9Y5X9 9/20 0.35
DGAT1 O75907 1/20 0.34
CSF1R P07333 1/20 0.33
ALPL P05186 1/20 0.33
FFAR1 O14842 1/20 0.33
EGFR P00533 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23062820 0.83 SNCA (0.44) SNCAIRAK4IDO1TDO2LPL
SCHEMBL29612564 0.80 SNCA (0.41) SNCAIRAK4IDO1TDO2LPL
SCHEMBL19836331 0.80 SNCA (0.41) SNCAIRAK4IDO1TDO2LPL
SCHEMBL29612502 0.79 SNCA (0.41) SNCAIRAK4IDO1TDO2LPL
SCHEMBL24668140 0.79 SNCA (0.41) SNCAIRAK4IDO1TDO2LPL
SCHEMBL23042340 0.78 SNCA (0.40) SNCAIRAK4IDO1TDO2LPL
SCHEMBL29729476 0.75 SNCA (0.38) SNCAIRAK4IDO1TDO2LPL
SCHEMBL24668910 0.73 NPM1 (0.42)
SCHEMBL23061560 0.73 ESR1 (0.36)
SCHEMBL18130872 0.71 IRAK4 (0.39) SNCAIRAK4IDO1TDO2LPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528791-B2 Thyroid hormone receptor beta agonist compounds TERNS PHARMACEUTICALS, INC. (US) 2026-01-20 US disclosed
US-20240059682-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS TERNS PHARMACEUTICALS, INC. 2024-02-22 US disclosed
EP-4301357-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns Pharmaceuticals, Inc. (US) 2024-01-10 EP disclosed
WO-2022187403-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS TERNS PHARMACEUTICALS, INC. (US) 2022-09-09 WO disclosed
WO-2022187403-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS TERNS PHARMACEUTICALS, INC. (US) 2022-09-09 WO disclosed
US-20220281849-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS TERNS PHARMACEUTICALS, INC. 2022-09-08 US disclosed
EP-4017875-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns Pharmaceuticals, Inc. (US) 2022-06-29 EP disclosed
WO-2021041237-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. (US) 2021-03-04 WO disclosed
WO-2021041237-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. (US) 2021-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528791-B2 Thyroid hormone receptor beta agonist compounds THRB, THRA, TSHR SNCA 2690/4885IRAK4 3533/4885IDO1 1866/4885
US-20220281849-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS THRB, THRA, TSHR SNCA 3065/4885IRAK4 1862/4885IDO1 2264/4885
US-20240059682-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS THRB, THRA, TSHR SNCA 3199/4885IRAK4 1782/4885IDO1 2485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.